ClinicalTrials.gg
Active, not recruitingNCT06166836Updated Nov 12, 2026

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

A Phase 1/2 interventional study of D1553 and IN10018(Ifebemtinib) in Solid Tumor, sponsored by InxMed (Shanghai) Co., Ltd.. Active, not recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by InxMed (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2022, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 1b/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects with locally advanced or metastatic solid tumor with KRAS G12C mutation.

Read the detailed description

This study includes 2 phases: Phase Ib-Dose Escalation and Phase II-Dose Expansion. Phase Ib-Dose Escalation part will enroll at least 6 subjects to identify the safety and RP2D of D1553 in combination with IN10018 in KRAS G12C mutant solid tumors. Phase II-Dose Expansion part contains 3 cohorts with cohort A to enroll advanced colorectal cancer (CRC) with KRAS G12C mutation, cohort B to enroll advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation, and cohort C to enroll other advanced solid tumors with KRAS G12C mutation. Phase II study is to evaluate the safety and antitumor activities of D-1553 in combination with IN10018 in KRAS G12C mutant solid tumors. The sample size in each cohort is estimated per Simon's 2-stage design. In Cohort A, when Simon's 2-stage study achieved statistical hypothesis, an open-label, randomized study will be conducted for factorial analysis to evaluate the contribution of IN10018 in the combination regimen.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

InxMed (Shanghai) Co., Ltd. is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women aged ≥ 18 years at the time of signing the form.
  2. Subjects with confirmed locally advanced or solid tumors.
  3. Confirmed positive KRAS G12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells or DNA.
  4. Tumor types in different phases and cohorts: 1) Phase 1b: subjects with locally advanced or metastatic solid tumors who have progressed on or failed in standard therapy, and no standard treatment is available. 2) Phase II Cohort A: subjects with locally advanced or metastatic CRC. 3) Phase II Cohort B: subjects with locally advanced or metastatic NSCLC. 4) Phase 2 Cohort C: subjects with other locally advanced or metastatic solid tumors.
  5. Has at baseline according to 1.1 criteria.
  6. Has an (ECOG) performance status of 0 or 1.
  7. Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Prior KRAS G12C inhibitors treatment.
  2. Have known symptoms of spinal cord compression, instable or symptomatic central nervous system (CNS) , and/or carcinomatous meningitis.
  3. Have a history of stroke or other serious cerebrovascular diseases within 12 months prior to the first dose.
  4. Have had interstitial lung disease or any active infection requiring systemic treatment within 14 days prior to the first dose.
  5. Has a history of severe cardiovascular disease such as acute myocardial infarction, severe/unstable angina, prolongation, or poorly controlled hypertension.
  6. Haven't recovered from toxicity due to prior antitumor therapy
  7. Pregnant or lactating women.
  8. Malignant neoplasms other than study disease within 5 years prior to enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Phase 1b-Dose Escalation Part

    To evaluate the safety and Recommended Phase 2 dose (RP2D) of D-1553 in combination with IN10018 in previously-treated solid tumors.

    Drug: D1553 · Drug: IN10018(Ifebemtinib)

  • Experimental
    Phase II Cohort A-previously-treated CRC with KRAS G12C mutation(Treatmnt Group)

    To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in previously-treated CRCs with KRAS G12C mutation.

    Drug: D1553 · Drug: IN10018(Ifebemtinib)

  • Active comparator
    Phase II Cohort A-previously-treated CRC with KRAS G12C mutation (Control Group)

    To evaluate the safety and antitumor efficacy of D-1553 in previously-treated CRCs with KRAS G12C mutation.

    Drug: D1553

  • Experimental
    Phase II Cohort B-treatment-naïve or previously-treated NSCLC with KRAS G12C mutation

    To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in advanced NSCLCs with KRAS G12C mutation.

    Drug: D1553 · Drug: IN10018(Ifebemtinib)

  • Experimental
    Phase II Cohort C-other previously-treated solid tumors with KRAS G12C mutation

    To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in other solid tumors with KRAS G12C mutation

    Drug: D1553 · Drug: IN10018(Ifebemtinib)

Interventions

06

What researchers measure

Primary outcomes

  1. Recommended phase II dose (RP2D) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation

    Evaluate the number of patients with dose-limited toxicities (DLTs); Determine the RP2D of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation.

    Time frame: Through study completion, approximately 3 years

  2. Objective Response Rate (ORR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation

    Defined as the proportion of subjects with complete response (CR) or partial response (PR).

    Time frame: Through study completion, approximately 3 years

Secondary outcomes

  1. Progression-free Survival (PFS) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation

    Defined as the time from the first dose of study treatment to first documentation of disease progression or to death due to any cause, whichever comes first.

    Time frame: Through study completion, approximately 3 years

  2. Duration of Response (DoR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation

    Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first.

    Time frame: Through study completion, approximately 3 years

  3. Disease Control Rate (DCR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation

    Defined as the proportion of patients with CR, PR, or stable disease (SD).

    Time frame: Through study completion, approximately 3 years

  4. Overall survival (OS) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation

    Defined as the time from the first dose of study treatment to the date of death due to any cause.

    Time frame: Through study completion, approximately 3 years

  5. Number of subjects with adverse event

    The number of subjects who experienced AEs is presented.

    Time frame: Through study completion, approximately 3 years

  6. Plasma concentrations of D-1553 and IN10018 in solid tumors with KRAS G12C mutation

    Plasma concentrations of D-1553 and IN10018

    Time frame: Through study completion, approximately 3 years

  7. PK: Cmax of D-1553 and IN10018

    Maximum concentration (Cmax)

    Time frame: Through study completion, approximately 3 years

  8. PK: Cmin of D-1553 and IN10018

    Minimum concentration (Cmin)

    Time frame: Through study completion, approximately 3 years

  9. PK:t1/2 of D-1553 and IN10018

    Elimination half-life (t1/2).

    Time frame: Through study completion, approximately 3 years

  10. PK:CL/F of D-1553 and IN10018

    apparent clearance (CL/F)

    Time frame: Through study completion, approximately 3 years

  11. PK:Vd/F of D-1553 and IN10018

    Apparent volume of distribution (Vd/F)

    Time frame: Through study completion, approximately 3 years

  12. PK: AUC of D-1553 and IN10018

    Area under the concentration-time curve (AUC)

    Time frame: Through study completion, approximately 3 years

07

Study locations

10 sites
08

References and documents

Publications

  • Song Z, Zhu L, Liu Y, Lin R, Li X, Luo Y, Yuan Y, Shi H, Zhang Y, Zhang B, Zhu Y, Wang Z, Cheng X. Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial. Lancet Oncol. 2026 Sep;27(9):1133-1145. doi: 10.1016/S1470-2045(26)00175-0. PubMed 42636835 ↗
  • Song Z, Li X, Lin R, Shi H, Yuan Y, Liu Y, Luo Y, Lv T, Zhang Y, Zhu L, Zhu Y, Zhang L, Wang Z. Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial. Lancet Respir Med. 2026 Jul 7:S2213-2600(26)00142-6. doi: 10.1016/S2213-2600(26)00142-6. Online ahead of print. PubMed 42413526 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Dec 2027, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Dec 12, 2023
StartActual
Oct 12, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42636835 ↗
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42636835 ↗
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06166836
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Dec 12, 2023
Start date
Oct 12, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Zhengbo Song
principal investigator · Study Principal Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion